A recent study raises safety concerns associated with the use of varenicline among tobacco users. Use of the drug was associated with a 72% increased risk of serious adverse cardiovascular events and deserves further investigation, according to results of the study, which was published July 4 in the Canadian Medical Association Journal.
A recent study raises safety concerns associated with the use of varenicline among tobacco users. Use of the drug was associated with a 72% increased risk of serious adverse cardiovascular events and deserves further investigation, according to results of the study, which was published July 4 in the Canadian Medical Association Journal.
Investigators searched MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, Regulatory websites, and clinical trial registries in September 2010. An updated search was conducted in March 2011. Included in the study were 14 double-blind, randomized placebo-controlled trials of 8,216 participants with treatment duration ranging from 7 to 52 weeks that evaluated varenicline as the intervention drug versus a placebo among tobacco users and in which serious adverse cardiovascular events were reported.
The meta-analysis showed a significantly increased risk of serious adverse cardiovascular events associated with varenicline compared with placebo. Sensitivity analyses each showed results similar to the primary analysis.
“The robustness of the effect size to alternative statistical approaches or comparators in various sensitivity analyses suggests that this safety signal deserves further investigation,” the authors wrote. “Despite the limitations of our analysis, our findings
have potential regulatory and clinical implications,” the authors added.
At the time of the study’s publication, FDA released a safety announcement about varenicline (Chantix) stating that it may be associated with a small, increased risk of certain cardiovascular adverse events in patients who have cardiovascular disease, and the safety information would be added to the Warnings and Precautions section of the physician labeling. In addition, the patient Medication Guide would be revised accordingly.
FDA’s decision was based on the review of a randomized clinical trial of 700 smokers with cardiovascular disease who were treated with Chantix or placebo. Although adverse events were generally infrequent and Chantix was effective at helping patients quit and abstain from smoking for as long as a year, certain events, including heart attack, were reported more frequently in patients treated with Chantix over placebo.
FDA advised healthcare practitioners deciding to prescribe the drug to smokers with cardiovascular disease to weigh the known benefits against its potential risks. The agency added that it is continuing to evaluate the cardiovascular safety of the drug and has required Pfizer, the drug’s manufacturer, to conduct a large, meta-analysis of randomized, placebo-controlled trials.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.